Bliss GVS Pharma Share Price Target Tomorrow 2024 To 2030- Market Overview, Financials

Bliss GVS Pharma Ltd is an Indian pharmaceutical company known for making affordable, high-quality healthcare products. Established in 1984, it focuses on developing, manufacturing, and exporting medicines, including tablets, creams, and suppositories.

The company is recognized for its expertise in suppositories and pessaries, offering innovative drug delivery solutions for patients worldwide. Bliss GVS serves healthcare needs in over 60 countries, with a strong presence in Africa, Southeast Asia, and Latin America. Bliss GVS Pharma Share Price on NSE as of 2 December 2024 is 167.20 INR. Here will provide you more details on Bliss GVS Pharma Share Price Target 2024, 2025, 2026 to 2030.

Bliss GVS Pharma Ltd: Market Overview

• Open Price: ₹164.89
• High Price: ₹172.42
• Low Price: ₹162.55
• Previous Close: ₹161.78
• Volume: 5,168,309
• Value (Lacs): ₹8,680.17
• VWAP: ₹169.03
• UC Limit: ₹194.13
• LC Limit: ₹129.42
• P/E ratio: 28.13
• Div yield: 0.30%
• 52-wk high: ₹172.42
• 52-wk low: ₹92.15
• Mkt cap: ₹1.57KCr
• Face Value: ₹1

Bliss GVS Pharma Share Price Chart

Bliss GVS Pharma Share Price Target Tomorrow 2024 To 2030

Bliss GVS Pharma Share Price Target 2024

Bliss GVS Pharma share price target 2024 Expected target could be ₹176. Here are four key factors that could affect Bliss GVS Pharma’s share price target in 2024:

1. Product Innovation and Expansion: Launching new products, especially in niche areas like suppositories and pessaries, can drive growth. Expansion into new markets and therapeutic categories will also boost revenue and investor confidence.
2. Global Healthcare Demand: Rising demand for affordable medicines, especially in emerging markets like Africa and Southeast Asia, where the company has a strong presence, will play a significant role in its growth.
3. Regulatory Approvals: Securing approvals for new products from international health authorities (e.g., USFDA, WHO) is crucial for expanding the company’s global footprint and gaining trust, which can positively impact share performance.

4. Cost Management and Margins: Effective management of manufacturing costs and maintaining healthy profit margins amidst fluctuating raw material prices will be essential for profitability and sustained growth in 2024.

Bliss GVS Pharma Share Price Target 2025

Bliss GVS Pharma share price target 2025 Expected target could be ₹125. Here are four key factors that could affect Bliss GVS Pharma’s share price target in 2025:

1. Geographical Expansion: Increasing its reach in high-potential markets like Asia, Latin America, and Africa will be crucial. Expanding its global distribution network can drive higher sales and revenue growth.
2. Product Portfolio Diversification: Introducing new products across different therapeutic areas or enhancing existing formulations could strengthen the company’s market position and attract a wider customer base.
3. Regulatory Compliance and Quality Standards: Maintaining compliance with international regulatory bodies and ensuring high-quality manufacturing will boost investor trust and allow entry into more regulated markets, such as Europe and the US.

4. Partnerships and Collaborations: Strategic alliances with other pharmaceutical companies or healthcare organizations could enhance research and development, improve market penetration, and provide additional revenue streams.

Bliss GVS Pharma Share Price Target 2030

Bliss GVS Pharma share price target 2030 Expected target could be ₹510. Here are four risks and challenges that could impact Bliss GVS Pharma’s share price target in 2030:

1. Regulatory Hurdles: Stringent global regulations and delays in product approvals from health authorities like the USFDA or WHO could hinder the company’s ability to launch new products and expand into regulated markets.
2. Intense Competition: The pharmaceutical industry is highly competitive. Larger global players or low-cost generic manufacturers could challenge Bliss GVS Pharma’s market share, especially in its core markets.
3. R&D and Innovation Risks: Failure to invest in research and development or innovate new products to meet evolving healthcare needs could result in a stagnating product portfolio, limiting growth opportunities.

4. Economic and Geopolitical Instability: Economic slowdowns or geopolitical issues in key markets like Africa or Southeast Asia could disrupt operations, reduce demand for its products, and impact revenue.

Shareholding Pattern For Bliss GVS Pharma Ltd

• Promoters: 34.82%
• Retail and Others: 46.49%
• FII: 12.13%
• DII: 6.56%

Bliss GVS Pharma Ltd Financials

Read Also:- Bharat Gears Share Price Target Tomorrow 2024 To 2030- Market Overview, Financials